GE HealthCare Technologies posted fourth-quarter results Wednesday that exceeded analyst expectations while showcasing the growing importance of artificial intelligence in medical imaging. The company reported earnings of $1.44 per share—beating the $1.41 consensus—and announced a record equipment backlog of $21.8 billion that provides visibility into revenue for years to come.

The results positioned GE HealthCare as a standout in a healthcare sector that has struggled to find its footing amid policy uncertainty and shifting investor preferences. While peers like Boston Scientific and Novo Nordisk suffered double-digit stock declines this week, GE HealthCare shares gained modestly following the report.

Pharmaceutical Diagnostics Leads Growth

The star performer in the quarter was the pharmaceutical diagnostics segment, which includes contrast agents and molecular imaging compounds used in PET and CT scans. Revenue in this division grew 12.7% organically, with operating income climbing 10% as higher volumes drove operating leverage.

Management attributed the strength to increased procedure volumes for cancer diagnostics and cardiovascular imaging, as well as new product launches that have expanded the addressable market. The Alzheimer's imaging space has been particularly strong following approval of new PET tracers that can detect amyloid plaques associated with the disease.

"Our pharmaceutical diagnostics business is benefiting from precision medicine tailwinds that we expect to persist for years. As therapies become more targeted, the need for diagnostic precision increases correspondingly."

— Peter Arduini, CEO, GE HealthCare

AI-Powered Device Clearances Accelerate

GE HealthCare announced several significant regulatory milestones during the quarter that underscore its commitment to embedding artificial intelligence across its product portfolio:

  • Allia Moveo mobile C-arm: Received FDA clearance and CE mark for this next-generation surgical imaging system featuring AI-powered guidance and a compact design that enables easier deployment in operating rooms
  • Omni 128cm total body PET/CT: Obtained CE Mark for a revolutionary scanner that can image the entire body in a single pass, dramatically reducing scan times while improving diagnostic accuracy
  • SIGNA MRI next-generation platform: Unveiled at RSNA conference with AI-enhanced image reconstruction that reduces scan times by up to 50% while improving image quality

These products address a critical pain point for healthcare systems: the need to increase imaging throughput without sacrificing diagnostic quality. AI-enhanced systems can help hospitals process more patients while potentially improving outcomes through earlier and more accurate disease detection.

Record Backlog Provides Visibility

Perhaps the most reassuring data point for investors was the record equipment backlog of $21.8 billion, representing a book-to-bill ratio of approximately 1.06. This means the company is booking more new orders than it is delivering, indicating sustained demand momentum.

The backlog has grown consistently over the past two years as hospital systems have embarked on equipment refresh cycles and expanded imaging capacity to address procedure backlogs that built up during the pandemic. With hospitals still working through these capacity expansions, GE HealthCare has visibility into revenue extending well into 2028.

Management noted that more than $7 billion in enterprise deals—large contracts with major health systems—have been signed since the company's spin-off from General Electric in early 2023. These multi-year agreements provide stable, recurring revenue streams.

2026 Guidance: Cautious but Positive

For 2026, GE HealthCare guided to organic revenue growth of 3-4%, with adjusted earnings per share of $4.95 to $5.15, representing 8-12% growth from 2025 levels. The guidance incorporates several assumptions:

  • Continued strong demand in North America and Europe
  • Cautious outlook for China, where government procurement policies have created pricing pressure
  • Margin expansion from operational efficiency initiatives
  • Modest benefit from new product launches in the second half

While the growth outlook is modest compared to some other healthcare technology companies, it reflects the large-equipment nature of GE HealthCare's business, where multi-year sales cycles and long product lifespans limit the pace of revenue acceleration.

The AI Healthcare Opportunity

GE HealthCare's results illustrate a broader theme emerging in healthcare technology: AI is transitioning from a research curiosity to a clinical necessity. Hospitals and imaging centers are increasingly prioritizing AI-enabled equipment that can improve radiologist productivity, enhance diagnostic accuracy, and reduce the time patients spend in scanners.

The company estimates that its AI-enhanced products command pricing premiums of 5-15% compared to conventional alternatives, while also driving higher utilization rates that generate ongoing service revenue. As the installed base of AI-enabled equipment grows, this creates a virtuous cycle of data generation that further improves the AI algorithms.

Investment Implications

GE HealthCare's strong quarter and record backlog provide reassurance to investors who have been nervous about the healthcare sector. The company's steady execution and visibility into future revenue contrast favorably with peers facing more volatile market conditions.

However, the 3-4% growth outlook is unlikely to excite investors seeking aggressive returns. GE HealthCare is perhaps best viewed as a defensive holding within healthcare technology—a company that should deliver consistent returns through economic cycles while gradually expanding margins as AI adoption drives pricing power.

For investors concerned about healthcare sector volatility, the company's combination of contracted backlog, AI innovation, and diversified end markets offers a relatively stable alternative to the higher-risk, higher-reward profiles of pharmaceutical and medical device growth stocks.